血清miR-345、miR-138及miR-22与晚期胃癌患者化疗敏感性的相关性分析

doi:10.3969/j.issn.1671-7171.2024.05.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1232 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore serum microRNA-345 (miR-345) The correlation between miR-138 and miR-22 and chemotherapy sensitivity in advanced gastric cancer patients. 【Methods】A total of 100 patients with advanced gastric cancer who received the same chemotherapy regimen were divided into an effective group of 69 cases and an ineffective group of 31 cases based on their efficacy. The clinical and pathological characteristics and serum related indicators of the two groups were compared, and the receiver operating characteristic (ROC) curve was plotted. The serum miR-345 was analyzed. The value of miR-138 and miR-22 in predicting the chemotherapy efficacy of advanced gastric cancer was analyzed using multivariate logistic regression to identify the factors that affect the chemotherapy efficacy of patients.【Results】The relative expression level of serum miR-345 in stage Ⅲ patients was low than those of stage Ⅳ patients (P<0.05). The relative expression levels of miR-138 and miR-22 were higher than those of stage Ⅳ patients (P<0.05); miR-345 in the effective group was lower than that in the ineffective group, miR-138 and miR-22 were higher than those in the ineffective group (P<0.05). Confirmed by ROC analysis, serum miR-345, miR-138 and miR-22 can be used to predict the chemotherapy efficacy of advanced gastric cancer, with sensitivity and specificity of 0.855, 0.935, 0.971, 0.839, and 0.884, 0.903, respectively (all P<0.05). Multivariate logistic regression analysis showed that the pathological stage Ⅳ, miR-345 ≥ 14.5, miR-138 ≤ 2, and miR-22 ≤ 3.12 were risk factors for poor chemotherapy efficacy in advanced gastric cancer patients (P<0.05).【Conclusion】Serum miR-345≥14.5, miR-138 ≤ 2 and miR-22 ≤ 3.12 are both risk factors for poor chemotherapy efficacy, and can be used as biological markers to evaluate the chemotherapy efficacy of patients.

Key words： Stomach Neoplasms MicroRNAs Antineoplastic Agents Correlation of Data

Received: 15 December 2023

PACS:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Shixia
	WANG Haili

Cite this article:

ZHOU Shixia,WANG Haili. Correlation Analysis of Serum miR-345, miR-138 and miR-22 with Chemotherapy Sensitivity in Advanced Gastric Cancer Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 711-714.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.05.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I5/711

[1] 吴秀贞, 刘宗超, 覃向向,等.基于胃癌高发区人群筛查队列的不同胃黏膜病变进展为胃癌风险的前瞻性研究[J].中华流行病学杂志,2022,43(12):1972-1978.
[2] 李刚刚, 孙继锋, 张成武, 等. 早期胃癌淋巴结转移危险因素及预后分析[J].中华普通外科杂志,2021,36(10):734-738.
[3] YAMADA T,YOSHIKAWA T,MIZUSAWA J,et al. Risk factors for the continuation of S-1 adjuvant chemotherapy for gastric cancer analyzed from the JCOG1104 phase Ⅲ trial[J].J Clin Oncol,2021, 39(3):196.
[4] 唐德平, 邢梦洁, 宋文涛,等. microRNA治疗在癌症及其他疾病中的研究进展[J].中国生物工程杂志, 2021,41(11):64-73.
[5] ZHANG M Y,LIN J,KUI Y C,et al. MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1[J].Eur Rev Med Pharmacol Sci,2019,23(6):2436-2443.
[6] 吴闽, 侯慧珍, 司廷林. 过表达miR-138抑制TCF-4对甲状腺癌细胞CAL-62增殖、凋亡和运动的调节作用[J].中国临床解剖学杂志, 2019,37(4):425-430.
[7] YUAN S K, ZHANG P T, WEN L Q, et al. miR-22 promotes stem cell traits via activating Wnt/beta-catenin signaling in cutaneous squamous cell carcinoma[J].Oncogene,2021,40(39):5799-5813.
[8] 邱海波, 周志伟. NCCN胃癌临床实践指南2017年第五版更新要点解读[J].中华胃肠外科杂志, 2018,21(2):160-164.
[9] 李欣, 赵久达, 林明哲,等. 老年胃癌患者循环肿瘤细胞与临床病理特征及化疗疗效的关系[J].中国老年学杂志, 2022, 42(3):553-557.
[10] KUMAR S,SESHADRI R A, TRIVADI S G,et al. Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis[J].Asia-Pac J Clin Oncol,2020,16(5):252-256.
[11] HIRAKU Y,WATANABE J,KANEKO A,et al. MicroRNA expression in lung tissues of asbestos-exposed mice: Upregulation of miR-21 and downregulation of tumor suppressor genes Pdcd4 and Reck[J].J Occup Health,2021,63(1):12282.
[12] 孙婧悦, 王啸, 王振欣,等. 血清外泌体miRNAs在晚期胃癌患者化疗疗效预测中的价值[J].中国肿瘤临床, 2022,49(4):174-178.
[13] SONG J,LIU Y J, WANG T Y, et al. MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer[J].Biomed Pharmacother,2020,128(7):110246.
[14] ISHIKAWA M,HAYASHI H,SAKAMOTO N,et al. Cancer gene profiling explores the possible precision medicine for diffuse-type gastric adenocarcinoma[J].Med Oncol,2020, 37(1):10.
[15] SOUDEN G F,VAFAEE R,SHOOREI H,et al. MicroRNAs in gastric cancer: Biomarkers and therapeutic targets[J].Gene,2020, 757(10):144937.
[16] YIN C L, ZHENG X X, XIANG H P, et al. Differential expression profile analysis of cisplatin-regulated miRNAs in a human gastric cancer cell line[J].Mol Med Rep,2019,20(2):1966-1976.